{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:40:15Z","timestamp":1783478415363,"version":"3.55.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"DOI":"10.1186\/s13044-025-00276-1","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:01:35Z","timestamp":1764889295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Graves\u2019 orbitopathy following Alemtuzumab treatment for multiple sclerosis: a systematic review and real-world insights"],"prefix":"10.1186","volume":"18","author":[{"given":"Bohdan","family":"Patera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotiris","family":"Louka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Piantanida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Tanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"276_CR1","doi-asserted-by":"crossref","unstructured":"Wiersinga WM. Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. Endocrinol Metab (Seoul). 2016 June;31(2):213\u201322.","DOI":"10.3803\/EnM.2016.31.2.213"},{"issue":"2","key":"276_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12020-012-9703-2","volume":"42","author":"DSA McLeod","year":"2012","unstructured":"McLeod DSA, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252\u201365.","journal-title":"Endocrine"},{"issue":"4","key":"276_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1530\/EJE-06-0651","volume":"156","author":"F Yang","year":"2007","unstructured":"Yang F, Shan Z, Teng X, Li Y, Guan H, Chong W, et al. Chronic iodine excess does not increase the incidence of hyperthyroidism: a prospective community-based epidemiological survey in China. Eur J Endocrinol. 2007;156(4):403\u20138.","journal-title":"Eur J Endocrinol"},{"key":"276_CR4","doi-asserted-by":"crossref","unstructured":"Brent GA. Clinical practice. Graves\u2019 disease. N Engl J Med. 2008 June;12(24):2594\u2013605.","DOI":"10.1056\/NEJMcp0801880"},{"issue":"4","key":"276_CR5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1210\/jc.2012-3873","volume":"98","author":"ML Tanda","year":"2013","unstructured":"Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, et al. Prevalence and natural history of graves\u2019 orbitopathy in a large series of patients with newly diagnosed graves\u2019 hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013;98(4):1443\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"276_CR6","doi-asserted-by":"crossref","unstructured":"Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, et al. Graves\u2019 disease. Nat Rev Dis Primers. 2020 July;2(1):52.","DOI":"10.1038\/s41572-020-0184-y"},{"key":"276_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fendo.2020.00406","volume":"11","author":"D Gallo","year":"2020","unstructured":"Gallo D, Piantanida E, Gallazzi M, Bartalena L, Tanda ML, Bruno A, et al. Immunological drivers in graves\u2019 disease: NK cells as a master switcher. Front Endocrinol (Lausanne). 2020;11:406.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"276_CR8","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/joim.13524","volume":"292","author":"L Bartalena","year":"2022","unstructured":"Bartalena L, Tanda ML. Current concepts regarding Graves\u2019 orbitopathy. J Intern Med. 2022;292(5):692\u2013716.","journal-title":"J Intern Med"},{"issue":"4","key":"276_CR9","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European group on graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves\u2019 orbitopathy. Eur J Endocrinol. 2021;185(4):G43\u201367.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"276_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1210\/jc.2012-3119","volume":"98","author":"KA Ponto","year":"2013","unstructured":"Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ. Public health relevance of graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2013;98(1):145\u201352.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"276_CR11","first-page":"473","volume":"120","author":"C Marcocci","year":"1989","unstructured":"Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves\u2019 disease. Acta Endocrinol (Copenh). 1989;120(4):473\u20138.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"276_CR12","doi-asserted-by":"crossref","unstructured":"Laurberg P, Berman DC, B\u00fclow Pedersen I, Andersen S, Carl\u00e9 A. Incidence and clinical presentation of moderate to severe graves\u2019 orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab. 2012 July;97(7):2325\u201332.","DOI":"10.1210\/jc.2012-1275"},{"issue":"9856","key":"276_CR13","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829\u201339.","journal-title":"Lancet"},{"issue":"1","key":"276_CR14","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1212\/NXI.0000000000000194","volume":"3","author":"S De Mercanti","year":"2016","unstructured":"De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, et al. Alemtuzumab long-term Immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm. 2016;3(1):e194.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"276_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","volume":"86","author":"O Tuohy","year":"2015","unstructured":"Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015;86(2):208\u201315.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"276_CR16","first-page":"205521732093392","volume":"6","author":"SM Yap","year":"2020","unstructured":"Yap SM, Dillon M, Crowley RK, McGuigan C. Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset. Mult Scler J Exp Transl Clin. 2020;6(2):2055217320933928.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"8","key":"276_CR17","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","volume":"74","author":"D Baker","year":"2017","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol. 2017;74(8):961\u20139.","journal-title":"JAMA Neurol"},{"key":"276_CR18","doi-asserted-by":"publisher","first-page":"205873841984369","DOI":"10.1177\/2058738419843690","volume":"33","author":"A Alamo","year":"2019","unstructured":"Alamo A, Condorelli RA, La Vignera S, Calogero AE. Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis. Int J Immunopathol Pharmacol. 2019;33:2058738419843690.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"276_CR19","doi-asserted-by":"crossref","unstructured":"Ruck T, Barman S, Schulte-Mecklenbeck A, Pfeuffer S, Steffen F, Nelke C, et al. Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. Brain. 2022 June 3;145(5):1711\u201325.","DOI":"10.1093\/brain\/awac064"},{"issue":"1","key":"276_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1210\/jc.2013-2201","volume":"99","author":"GH Daniels","year":"2014","unstructured":"Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014;99(1):80\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"276_CR21","first-page":"205521732211427","volume":"9","author":"CM Dayan","year":"2023","unstructured":"Dayan CM, Lecumberri B, Muller I, Ganesananthan S, Hunter SF, Selmaj KW, et al. Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. Mult Scler J Exp Transl Clin. 2023;9(1):20552173221142741.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"276_CR22","doi-asserted-by":"crossref","unstructured":"Muller I, Moran C, Lecumberri B, Decallonne B, Robertson N, Jones J, et al. 2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy. Eur Thyroid J. 2019 July;8(4):173\u201385.","DOI":"10.1159\/000500881"},{"key":"276_CR23","doi-asserted-by":"publisher","first-page":"105880","DOI":"10.1016\/j.msard.2024.105880","volume":"91","author":"JF Hansen","year":"2024","unstructured":"Hansen JF, Magyari M, Rasmussen \u00c5K, Sellebjerg F, Feldt-Rasmussen U. Alemtuzumab-induced thyroid disease: A Danish cohort study. Mult Scler Relat Disord. 2024;91:105880.","journal-title":"Mult Scler Relat Disord"},{"issue":"9191","key":"276_CR24","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","volume":"354","author":"AJ Coles","year":"1999","unstructured":"Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354(9191):1691\u20135.","journal-title":"Lancet"},{"issue":"6","key":"276_CR25","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1097\/IOP.0000000000000310","volume":"32","author":"T Trinh","year":"2016","unstructured":"Trinh T, Haridas AS, Sullivan TJ. Ocular findings in alemtuzumab (Campath-1H)-induced thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2016;32(6):e128\u20139.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"276_CR26","doi-asserted-by":"crossref","unstructured":"Sovetkina A, Nadir R, Scalfari A, Tona F, Murphy K, Rigoni E, et al. Development of autoimmune thyroid disease in multiple sclerosis patients post-alemtuzumab improves treatment response. J Clin Endocrinol Metab. 2020 Sept 1;105(9):dgaa453.","DOI":"10.1210\/clinem\/dgaa453"},{"key":"276_CR27","doi-asserted-by":"crossref","first-page":"D229","DOI":"10.1111\/ene.12626","volume":"22","author":"T Ziemssen","year":"2015","unstructured":"Ziemssen T, Selmaj KW, Vermersch P. Quality-of-life improvements with alemtuzumab are maintained in relapsing-remitting multiple sclerosis patients who develop thyroid adverse events in CARE-MS II. Eur J Neurol. 2015;22:D229.","journal-title":"Eur J Neurol"},{"issue":"8","key":"276_CR28","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1210\/jc.2018-00359","volume":"103","author":"N Pariani","year":"2018","unstructured":"Pariani N, Willis M, Muller I, Healy S, Nasser T, McGowan A, et al. Alemtuzumab-Induced thyroid dysfunction exhibits distinctive clinical and immunological features. J Clin Endocrinol Metab. 2018;103(8):3010\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"276_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40618-019-01105-7","volume":"43","author":"L Scappaticcio","year":"2020","unstructured":"Scappaticcio L, Castellana M, Virili C, Bellastella G, Centanni M, Cannav\u00f2 S, et al. Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. J Endocrinol Invest. 2020;43(2):219\u201329.","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"276_CR30","first-page":"e230236","volume":"13","author":"I Muller","year":"2024","unstructured":"Muller I, Maioli S, Armenti M, Porcaro L, Curr\u00f2 N, Iofrida E, et al. Alemtuzumab-induced thyroid eye disease successfully treated with a single low dose of rituximab. Eur Thyroid J. 2024;13(2):e230236.","journal-title":"Eur Thyroid J"},{"issue":"6","key":"276_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1212\/WNL.0b013e318228bec5","volume":"77","author":"M Cossburn","year":"2011","unstructured":"Cossburn M, Pace AA, Jones J, Ali R, Ingram G, Baker K, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573\u20139.","journal-title":"Neurology"},{"issue":"17","key":"276_CR32","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"CAMMS Coles","year":"2008","unstructured":"Coles CAMMS, Trial Investigators AJ, Compston DAS, Selmaj KW, Lake SL, Moran S, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786\u2013801.","journal-title":"N Engl J Med"},{"issue":"4","key":"276_CR33","first-page":"e24570","volume":"14","author":"S AlShehri","year":"2022","unstructured":"AlShehri S, Alajmi S, Ekhzaimy A, Aldawas S, Alalwan M. Thyroid storm in a patient with Alemtuzumab-Induced Graves\u2019 disease: A case report. Cureus. 2022;14(4):e24570.","journal-title":"Cureus"},{"key":"276_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fendo.2017.00254","volume":"8","author":"M Rotondi","year":"2017","unstructured":"Rotondi M, Molteni M, Leporati P, Capelli V, Marin\u00f2 M, Chiovato L. Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: an example of selective anti-TSH-Receptor immune response. Front Endocrinol (Lausanne). 2017;8:254.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"276_CR35","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1089\/thy.2018.0232","volume":"28","author":"I Muller","year":"2018","unstructured":"Muller I, Willis M, Healy S, Nasser T, Loveless S, Butterworth S, et al. Longitudinal characterization of autoantibodies to the Thyrotropin receptor (TRAb) during alemtuzumab therapy: evidence that trab May precede thyroid dysfunction by many years. Thyroid. 2018;28(12):1682\u201393.","journal-title":"Thyroid"},{"key":"276_CR36","first-page":"368","volume":"103","author":"RP Yeatts","year":"2005","unstructured":"Yeatts RP. Quality of life in patients with graves ophthalmopathy. Trans Am Ophthalmol Soc. 2005;103:368\u2013411.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"276_CR37","doi-asserted-by":"crossref","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009 July;21:339:b2700.","DOI":"10.1136\/bmj.b2700"},{"key":"276_CR38","doi-asserted-by":"publisher","unstructured":"Patera B, Zaffaroni A, Louka S, Gallo D, Piantanida E, Tanda ML. Review protocol for \u2018Graves\u2019 orbitopathy following alemtuzumab treatment for multiple sclerosis: a systematic review and real-world insights\u2019 [Internet]. 2025. Available from: https:\/\/doi.org\/10.5281\/zenodo.15849890","DOI":"10.5281\/zenodo.15849890"},{"issue":"2","key":"276_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60\u20133.","journal-title":"BMJ Evid Based Med"},{"key":"276_CR40","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"276_CR41","unstructured":"R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing. 2024. Available from: https:\/\/www.R-project.org\/"},{"issue":"6","key":"276_CR42","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1007\/s10238-022-00981-3","volume":"23","author":"P Kazakou","year":"2023","unstructured":"Kazakou P, Tzanetakos D, Vakrakou AG, Tzartos JS, Evangelopoulos \u039cE, Anagnostouli M, et al. Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study. Clin Exp Med. 2023;23(6):2885\u201394.","journal-title":"Clin Exp Med"},{"issue":"2","key":"276_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41433-018-0282-1","volume":"33","author":"JCP Roos","year":"2019","unstructured":"Roos JCP, Moran C, Chatterjee VK, Jones J, Coles A, Murthy R. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering graves\u2019 orbitopathy: a case series. Eye (Lond). 2019;33(2):223\u20139.","journal-title":"Eye (Lond)"},{"key":"276_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/EB.S140481","volume":"9","author":"HE Moss","year":"2017","unstructured":"Moss HE. Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown. Eye Brain. 2017;9:13\u201321.","journal-title":"Eye Brain"},{"issue":"5","key":"276_CR45","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/IOP.0000000000002367","volume":"39","author":"A Nirmalan","year":"2023","unstructured":"Nirmalan A, Blecher N, Hyder S, Couch SM, Godfrey KJ, Stan MN, et al. Alemtuzumab-Induced thyroid eye disease: A comprehensive case series and review of the literature. Ophthalmic Plast Reconstr Surg. 2023;39(5):470\u20134.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"276_CR46","doi-asserted-by":"crossref","unstructured":"Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves\u2019 orbitopathy. Thyroid. 2010 July;20(7):785\u201393.","DOI":"10.1089\/thy.2010.1640"},{"key":"276_CR47","doi-asserted-by":"publisher","unstructured":"Bartalena L, Gallo D, Kahaly GJ, Piantanida E, Tanda ML. Process to radioactive iodine treatment for graves\u2019 hyperthyroidism: condemned or absolved? J Endocrinol Invest. 2025;48(9):1927\u20131950. https:\/\/doi.org\/10.1007\/s40618-025-02653-x","DOI":"10.1007\/s40618-025-02653-x"},{"key":"276_CR48","doi-asserted-by":"crossref","unstructured":"Edwards EK, Edwards EK. The simultaneous occurrence of Hailey-Hailey disease, Graves\u2019 disease and multiple sclerosis in the same patient. Acta Derm Venereol. 1997 July;77(4):332.","DOI":"10.2340\/0001555577332"},{"key":"276_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1740-2557-2-9","volume":"2","author":"JS Sloka","year":"2005","unstructured":"Sloka JS, Phillips PWEM, Stefanelli M, Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J Autoimmune Dis. 2005;2:9.","journal-title":"J Autoimmune Dis"},{"issue":"2","key":"276_CR50","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/BF02173310","volume":"226","author":"WW Bixenman","year":"1988","unstructured":"Bixenman WW, Buchsbaum HW. Multiple sclerosis, euthyroid restrictive grave\u2019s ophthalmopathy, and myasthenia gravis. A case report. Graefes Arch Clin Exp Ophthalmol. 1988;226(2):168\u201371.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"276_CR51","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.autrev.2018.10.001","volume":"18","author":"SM Ferrari","year":"2019","unstructured":"Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Benvenga S, et al. The association of other autoimmune diseases in patients with Graves\u2019 disease (with or without ophthalmopathy): review of the literature and report of a large series. Autoimmun Rev. 2019;18(3):287\u201392.","journal-title":"Autoimmun Rev"},{"key":"276_CR52","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fimmu.2017.00514","volume":"8","author":"JM Greer","year":"2017","unstructured":"Greer JM, Broadley S, Pender MP. Reactivity to novel autoantigens in patients with coexisting central nervous system demyelinating disease and autoimmune thyroid disease. Front Immunol. 2017;8:514.","journal-title":"Front Immunol"},{"issue":"4","key":"276_CR53","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2265.2010.03855.x","volume":"74","author":"AP Weetman","year":"2011","unstructured":"Weetman AP. Diseases associated with thyroid autoimmunity: explanations for the expanding spectrum. Clin Endocrinol (Oxf). 2011;74(4):411\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"276_CR54","doi-asserted-by":"publisher","first-page":"105103","DOI":"10.1016\/j.msard.2023.105103","volume":"80","author":"S Gautam","year":"2023","unstructured":"Gautam S, Bhattarai A, Shah S, Thapa S, Gyawali P, Khanal P, et al. The association of multiple sclerosis with thyroid disease: A meta-analysis. Mult Scler Relat Disord. 2023;80:105103.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"276_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/IOP.0b013e318030b06b","volume":"23","author":"AAV Cruz","year":"2007","unstructured":"Cruz AAV, Akaishi PMS, Vargas MA, de Paula SA. Association between thyroid autoimmune dysfunction and non-thyroid autoimmune diseases. Ophthalmic Plast Reconstr Surg. 2007;23(2):104\u20138.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"276_CR56","doi-asserted-by":"publisher","first-page":"644200","DOI":"10.3389\/fendo.2021.644200","volume":"12","author":"M Kelada","year":"2021","unstructured":"Kelada M, Avari P, Farag S, Akishar R, Jain R, Aziz A, et al. Association of other autoimmune diseases with thyroid eye disease. Front Endocrinol (Lausanne). 2021;12:644200.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"276_CR57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.aopr.2024.11.004","volume":"5","author":"L Ma","year":"2025","unstructured":"Ma L, Jiang X, Hou Z, Li D. Causal association between non-thyroidal autoimmune diseases and graves\u2019 ophthalmopathy: A Mendelian randomization study. Adv Ophthalmol Pract Res. 2025;5(1):66\u201372.","journal-title":"Adv Ophthalmol Pract Res"},{"issue":"3","key":"276_CR58","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40265-017-0692-6","volume":"77","author":"G Heath","year":"2017","unstructured":"Heath G, Airody A, Gale RP. The ocular manifestations of drugs used to treat multiple sclerosis. Drugs. 2017;77(3):303\u201311.","journal-title":"Drugs"},{"issue":"1","key":"276_CR59","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00415-023-11995-6","volume":"271","author":"P Rodr\u00edguez de Vera G\u00f3mez","year":"2024","unstructured":"Rodr\u00edguez de Vera G\u00f3mez P, M\u00e9ndez Muros M, Torres Cuadro A, Toyos S\u00e1enz de Miera FJ, L\u00f3pez Ruiz R, Guerrero V\u00e1zquez R, et al. Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis. J Neurol. 2024;271(1):486\u201396.","journal-title":"J Neurol"},{"issue":"4","key":"276_CR60","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/cen.14296","volume":"93","author":"YH Chin","year":"2020","unstructured":"Chin YH, Ng CH, Lee MH, Koh JWH, Kiew J, Yang SP, et al. Prevalence of thyroid eye disease in graves\u2019 disease: A meta-analysis and systematic review. Clin Endocrinol (Oxf). 2020;93(4):363\u201374.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"276_CR61","doi-asserted-by":"publisher","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","volume":"11","author":"L Bartalena","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML, Epidemiology. Natural History, risk Factors, and prevention of graves\u2019 orbitopathy. Front Endocrinol (Lausanne). 2020;11:615993.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"276_CR62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","volume":"38","author":"P Perros","year":"1993","unstructured":"Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf). 1993;38(4):367\u201372.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"276_CR63","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF03345276","volume":"27","author":"L Hegedi\u00fcs","year":"2004","unstructured":"Hegedi\u00fcs L, Brix TH, Vestergaard P. Relationship between cigarette smoking and graves\u2019 ophthalmopathy. J Endocrinol Invest. 2004;27(3):265\u201371.","journal-title":"J Endocrinol Invest"},{"issue":"300","key":"276_CR64","first-page":"325","volume":"83","author":"RJ Swingler","year":"1992","unstructured":"Swingler RJ, Compston DA. The morbidity of multiple sclerosis. Q J Med. 1992;83(300):325\u201337.","journal-title":"Q J Med"},{"issue":"20","key":"276_CR65","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. Selenium and the course of mild graves\u2019 orbitopathy. N Engl J Med. 2011;364(20):1920\u201331.","journal-title":"N Engl J Med"},{"key":"276_CR66","unstructured":"Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). FAERS Public Dashboard [Internet]. [cited 2025 Apr 2]. Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-adverse-event-reporting-system-faers]"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00276-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13044-025-00276-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00276-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:01:38Z","timestamp":1764889298000},"score":1,"resource":{"primary":{"URL":"https:\/\/thyroidresearchjournal.biomedcentral.com\/articles\/10.1186\/s13044-025-00276-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1186\/s13044-025-00276-1","relation":{},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; this study is a systematic review of previously published data. For the institutional case series, the existing guidelines of our local authorities do not require ethical approval for case reports and case series for <\u20095 patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"For the institutional case series, written informed consent for publication was obtained from all individual patients, and the procedures followed were in accordance with the ethical standards and with the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}